Allergan Inc (AGN) 208.47 $AGN
Uptrend Call Working As Allergan Stock Rises 24.8% (AGN)
Comtex SmarTrend(R) - Fri Dec 12, 4:49PM CST
SmarTrend identified an Uptrend for Allergan (AMEX:AGN) on September 11th, 2014 at $167.11. In approximately 3 months, Allergan has returned 24.75% as of today's recent price of $208.47.
AGN: 208.47 (-2.67)
After Yesterday's Decline of 1.26%, Allergan Offers Investors Better Value
Comtex SmarTrend(R) - Fri Dec 12, 4:03PM CST
Allergan (AMEX:AGN) traded in a range yesterday that spanned from a low of $208.47 to a high of $210.59. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $209.85 on volume of 2.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AGN: 208.47 (-2.67)
Cerebral Palsy - Pipeline Review, H2 2014
M2 - Fri Dec 12, 3:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/zdwf83/cerebral_palsy) has announced the addition of the "Cerebral Palsy - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cerebral Palsy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cerebral Palsy and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cerebral Palsy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cerebral Palsy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Allergan - Acorda Therapeutics, Inc. - Neuralstem, Inc. - CHA Bio & Diostech Co., Ltd. - K-Stemcell Co., Ltd. - Cell Cure Neurosciences, Ltd. - Cellular Biomedicine Group, Inc. For more information visit http://www.researchandmarkets.com/research/zd...bral_palsy
AGN: 208.47 (-2.67), ACOR: 38.70 (+0.06), CBMG: 14.10 (+0.12), CUR: 2.58 (-0.09)
Merck Reveals Data from Breast Cancer Study on Keytruda - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 11, 4:10PM CST
Merck (MRK) announced early data from the phase Ib study on its anti-PD-1 therapy, Keytruda.
AGN: 208.47 (-2.67), MRK: 57.72 (-1.62), BMY: 58.75 (-0.93)
Wilshire Confirms First-to-File Patent Challenge Relating to LASTACAFT®
PR Newswire - Thu Dec 11, 2:18PM CST
Wilshire Pharmaceuticals, Inc. ("Wilshire"
today confirmed that it has been sued by Allergan, Inc. and Vistakon Pharmaceuticals, LLC (collectively, "Allergan" in connection with Wilshire's filing of an Abbreviated New Drug Application ("ANDA" with the U.S. Food and Drug Administration ("FDA" for Alcaftadine (alcaftadine ophthalmic solution) 0.25%. This product is the generic version of LASTACAFT® (alcaftadine ophthalmic solution) 0.25%, which is indicated for the prevention of itching associated with allergic conjunctivitis.
AGN: 208.47 (-2.67)
Roche (RHHBY) Presents Positive Data on Haemophilia Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 4:16PM CST
Roche (RHHBY) announced data on its pipeline candidate ACE910 at the 56th American Society of Hematology.
AGN: 208.47 (-2.67), ABBV: 65.27 (-1.76), BIOD: 1.38 (-0.03)
Allergan Leads The 20 Best Value Bond Trades With A Maturity Of 1 Year Or More
Donald van Deventer - at Seeking Alpha - Wed Dec 10, 11:17AM CST
BDX: 136.99 (-1.03), BCR: 167.49 (-1.66), AXP: 91.00 (-2.13), TMO: 124.99 (-1.73), WBK: 26.10 (-0.46), AMT: 98.58 (-1.37), C: 53.40 (-1.11), AMGN: 164.53 (-1.55), CELG: 114.49 (-2.25), MCO: 93.47 (-2.70), AGN: 208.47 (-2.67), T: 32.16 (-0.55), GS: 188.82 (-4.72), JPM: 60.04 (-1.10), GILD: 104.13 (-0.18), MMP: 77.44 (-1.02)
The Zacks Analyst Blog Highlights: Novartis, Amgen, Incyte and Allergan
PR Newswire - Wed Dec 10, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Novartis (NYSE:NVS-Free Report), Amgen (Nasdaq:AMGN-Free Report), Incyte Corp. (Nasdaq:INCY-Free Report) and Allergan (NYSE:AGN-Free Report).
AGN: 208.47 (-2.67), INCY: 74.65 (-1.27), AMGN: 164.53 (-1.55), NVS: 93.52 (-0.82)
Herb Greenberg: What's Next for Valeant After Its Botched Bid for Allergan
at The Street - Wed Dec 10, 8:18AM CST
Has the pharmaceutical company really changed its strategy?
AGN: 208.47 (-2.67), VRX: 138.71 (-0.18)
Jim Cramer on the Stock Market: Activists Give Up on the Losers
at The Street - Wed Dec 10, 7:48AM CST
And that's too bad, because United Tech and McDonald's are begging for turnarounds.
AGN: 208.47 (-2.67), GE: 24.89 (-0.52), UTX: 112.15 (-1.89), MCD: 90.62 (-0.35), DOW: 43.35 (-2.66), WEN: 8.71 (+0.03), PEP: 94.74 (-1.55), BKW: 35.50 (-1.16)
Jim Cramer's 'Mad Money' Recap: Why Tuesday's Market Decline Made Sense
at The Street - Tue Dec 09, 7:32PM CST
The international markets pulled U.S. stocks lower but they were able to bounce back despite bad news from Verizon, Bank of America and Citi.
EA: 44.90 (-0.22), HON: 95.88 (-2.01), UTX: 112.15 (-1.89), C: 53.40 (-1.11), SNE: 20.33 (-0.41), BBY: 36.85 (+0.22), PEP: 94.74 (-1.55), AGN: 208.47 (-2.67), ATVI: 19.90 (-0.44), ETP: 60.56 (-1.13), SAVE: 68.12 (-0.88), TRGP: 92.56 (-0.45), WMB: 42.76 (-1.37), TEX: 26.48 (-0.43), AYR: 20.00 (-1.15), CAT: 90.50 (-2.19), MSFT: 46.95 (-0.22), UNP: 112.55 (-1.80), GME: 32.30 (-1.61), PDS: 5.39 (-0.07), BAC: 17.13 (-0.34), BKW: 35.50 (-1.16), MHR: 3.32 (-0.14), CONN: 17.44 (+0.35), MRK: 57.72 (-1.62), FLS: 54.87 (-2.45), MCD: 90.62 (-0.35), BRK.B: 146.46 (-3.67), VZ: 45.58 (-0.78), AMFW: 12.45 (-0.56), NRG: 26.66 (-0.26), WEN: 8.71 (+0.03)
Novartis Reports Encouraging Data on Biosimilar of Neupogen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 09, 2:15PM CST
Novartis (NVS) announced that its generic arm, Sandoz, reported encouraging data from a phase III study, PIONEER.
AGN: 208.47 (-2.67), INCY: 74.65 (-1.27), AMGN: 164.53 (-1.55), NVS: 93.52 (-0.82)
Wall Street Breakfast: China Stocks Tumble Most Since 2009
Wall Street Breakfast - Seeking Alpha - Tue Dec 09, 5:31AM CST
Economy European stocks fell for a second day as German imports and exports contracted in October, while Tesco ( OTCPK:TSCDF , OTCPK:TSCDY ) and energy companies plunged. German October imports slid 3.1% from a month earlier, while exports...
AMZN: 307.32 (-0.04), DRC: 80.82 (-0.03), VRX: 138.71 (-0.18), TLM: 4.29 (+0.60), C: 53.40 (-1.11), DB: 30.78 (-0.56), FIVE: 37.39 (+0.24), HSP: 60.33 (-1.75), ARO: 2.31 (+0.09), AGN: 208.47 (-2.67), PBR: 7.11 (-0.31), SPY: 200.89 (-3.30), QQQ: 102.67 (-1.13), CBST: 96.31 (+0.04), SMFG: 7.18 (-0.08), BHP: 46.18 (-0.92), MRK: 57.72 (-1.62), HMC: 29.34 (-0.72)
Bristol-Myers Posts Positive Opdivo Hodgkin Lymphoma Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 08, 4:10PM CST
Bristol-Myers Squibb Company (BMY) announced encouraging data from the ongoing phase Ib CheckMate - 039 study on Opdivo.
AGN: 208.47 (-2.67), ACT: 259.00 (-4.00), SGEN: 32.25 (-1.49), BMY: 58.75 (-0.93)
Agios (AGIO) Reports Encouraging Data on Leukemia Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 08, 3:35PM CST
Agios Pharmaceuticals, Inc. (AGIO) announced new data from the ongoing phase I dose escalation study on pipeline candidate AG-221.
AGN: 208.47 (-2.67), BIIB: 344.49 (+2.16), AGIO: 119.56 (+0.36), CELG: 114.49 (-2.25)
Novartis (NVS) Presents Additional Data on Leukemia Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 08, 2:30PM CST
Novartis (NVS) announced data on pipeline candidate, CTL019 from a long-term study of pediatric patients suffering from acute lymphoblastic leukemia (ALL).
AGN: 208.47 (-2.67), VRX: 138.71 (-0.18), ABBV: 65.27 (-1.76), NVS: 93.52 (-0.82)
Merck's New Oncology Product Positive in Early Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 08, 2:10PM CST
Merck (MRK) announced encouraging early results from the ongoing phase Ib study on Keytruda.
AGN: 208.47 (-2.67), SGEN: 32.25 (-1.49), MRK: 57.72 (-1.62), BMY: 58.75 (-0.93)
Is It Time to Buy This Growth Stock?
George Budwell, The Motley Fool - Motley Fool - Mon Dec 08, 8:43AM CST
Pharmaceutical stocks have absolutely soared amid the broader bull market. Shares of the specialist and generic drugmaker Actavis plc , for example, have more than tripled in value since 2012 alone: Actavis' rocket-like trajectory, though,...
AGN: 208.47 (-2.67), VRX: 138.71 (-0.18), ACT: 259.00 (-4.00), CBST: 96.31 (+0.04), PFE: 30.95 (-0.70), PDLI: 7.41 (-0.08)
Why 2014 Is the Biggest Year for Deals Since the Financial Crisis
at The Street - Mon Dec 08, 5:10AM CST
U.S. M&A jumped 38% in the first 10 months of the year from a year earlier, and is likely to mark the strongest year for deals since 2008 financial crisis.
ACT: 259.00 (-4.00), TERP: 27.50 (-1.34), MDT: 72.52 (-1.25), CHTR: 162.95 (-1.21), TWX: 82.12 (-1.19), AGN: 208.47 (-2.67), T: 32.16 (-0.55), FOX: 35.46 (-0.29), EBAY: 55.77 (-1.01), DTV: 83.47 (-0.43), JDSU: 13.81 (+0.06), GTIV: 19.05 (unch), WAG: 74.50 (+1.49), BHI: 54.99 (-0.78), KND: 18.61 (+0.54), ABT: 43.69 (-0.77), EXC: 35.92 (-0.35), COV: 100.49 (-1.36), HAL: 37.93 (-0.30), TSN: 40.80 (-0.93), HPQ: 38.01 (-0.46), SYMC: 25.26 (-0.58), ZTS: 41.77 (-1.11), POM: 26.66 (-0.30), SUNE: 18.55 (-0.47), GIS: 52.10 (-0.38), PETM: 77.67 (-0.77)
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2014
M2 - Mon Dec 08, 3:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/9mp6p4/wet_neovascular) has announced the addition of the "Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Wet (Neovascular / Exudative) Macular Degeneration - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Wet (Neovascular / Exudative) Macular Degeneration pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Alcon Nordic - Allergan - AlphaMab - Amakem - BIOCAD - Boehringer Ingelheim - Charlesson - Circadian Technologies - EyeCyte - EyeGate Pharmaceuticals - F. Hoffmann-La Roche - Genzyme - Icon Bioscience - Iconic Therapeutics - Intas Pharmaceuticals - Kala Pharmaceuticals - Lpath - Mesoblast - Neurotech Pharmaceuticals - Novartis - Ohr Pharmaceutical - Omeros Corporation - Ophthotech - Oxford BioMedica - PanOptica - Pfenex - Pfizer - Quark Pharmaceuticals - Regeneron Pharmaceuticals - Santen Pharmaceutical - Sanwa Kagaku Kenkyusho - Senju Pharmaceutical - TRACON Pharmaceuticals - Tacere Therapeutics - ThromboGenics - iCo Therapeutics - pSivida For more information visit http://www.researchandmarkets.com/research/9m...eovascular
AGN: 208.47 (-2.67), EYEG: (), OHRP: 8.55 (unch), REGN: 416.44 (-7.91), OMER: 22.81 (+0.12), NVS: 93.52 (-0.82)
Uptrend Call Working As Allergan Stock Rises 24.8% (AGN)
Comtex SmarTrend(R) - Fri Dec 12, 4:49PM CST
SmarTrend identified an Uptrend for Allergan (AMEX:AGN) on September 11th, 2014 at $167.11. In approximately 3 months, Allergan has returned 24.75% as of today's recent price of $208.47.
AGN: 208.47 (-2.67)
After Yesterday's Decline of 1.26%, Allergan Offers Investors Better Value
Comtex SmarTrend(R) - Fri Dec 12, 4:03PM CST
Allergan (AMEX:AGN) traded in a range yesterday that spanned from a low of $208.47 to a high of $210.59. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $209.85 on volume of 2.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AGN: 208.47 (-2.67)
Cerebral Palsy - Pipeline Review, H2 2014
M2 - Fri Dec 12, 3:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/zdwf83/cerebral_palsy) has announced the addition of the "Cerebral Palsy - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cerebral Palsy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cerebral Palsy and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cerebral Palsy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cerebral Palsy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Allergan - Acorda Therapeutics, Inc. - Neuralstem, Inc. - CHA Bio & Diostech Co., Ltd. - K-Stemcell Co., Ltd. - Cell Cure Neurosciences, Ltd. - Cellular Biomedicine Group, Inc. For more information visit http://www.researchandmarkets.com/research/zd...bral_palsy
AGN: 208.47 (-2.67), ACOR: 38.70 (+0.06), CBMG: 14.10 (+0.12), CUR: 2.58 (-0.09)
Merck Reveals Data from Breast Cancer Study on Keytruda - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 11, 4:10PM CST
Merck (MRK) announced early data from the phase Ib study on its anti-PD-1 therapy, Keytruda.
AGN: 208.47 (-2.67), MRK: 57.72 (-1.62), BMY: 58.75 (-0.93)
Wilshire Confirms First-to-File Patent Challenge Relating to LASTACAFT®
PR Newswire - Thu Dec 11, 2:18PM CST
Wilshire Pharmaceuticals, Inc. ("Wilshire"
today confirmed that it has been sued by Allergan, Inc. and Vistakon Pharmaceuticals, LLC (collectively, "Allergan" in connection with Wilshire's filing of an Abbreviated New Drug Application ("ANDA" with the U.S. Food and Drug Administration ("FDA" for Alcaftadine (alcaftadine ophthalmic solution) 0.25%. This product is the generic version of LASTACAFT® (alcaftadine ophthalmic solution) 0.25%, which is indicated for the prevention of itching associated with allergic conjunctivitis. AGN: 208.47 (-2.67)
Roche (RHHBY) Presents Positive Data on Haemophilia Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 4:16PM CST
Roche (RHHBY) announced data on its pipeline candidate ACE910 at the 56th American Society of Hematology.
AGN: 208.47 (-2.67), ABBV: 65.27 (-1.76), BIOD: 1.38 (-0.03)
Allergan Leads The 20 Best Value Bond Trades With A Maturity Of 1 Year Or More
Donald van Deventer - at Seeking Alpha - Wed Dec 10, 11:17AM CST
BDX: 136.99 (-1.03), BCR: 167.49 (-1.66), AXP: 91.00 (-2.13), TMO: 124.99 (-1.73), WBK: 26.10 (-0.46), AMT: 98.58 (-1.37), C: 53.40 (-1.11), AMGN: 164.53 (-1.55), CELG: 114.49 (-2.25), MCO: 93.47 (-2.70), AGN: 208.47 (-2.67), T: 32.16 (-0.55), GS: 188.82 (-4.72), JPM: 60.04 (-1.10), GILD: 104.13 (-0.18), MMP: 77.44 (-1.02)
The Zacks Analyst Blog Highlights: Novartis, Amgen, Incyte and Allergan
PR Newswire - Wed Dec 10, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Novartis (NYSE:NVS-Free Report), Amgen (Nasdaq:AMGN-Free Report), Incyte Corp. (Nasdaq:INCY-Free Report) and Allergan (NYSE:AGN-Free Report).
AGN: 208.47 (-2.67), INCY: 74.65 (-1.27), AMGN: 164.53 (-1.55), NVS: 93.52 (-0.82)
Herb Greenberg: What's Next for Valeant After Its Botched Bid for Allergan
at The Street - Wed Dec 10, 8:18AM CST
Has the pharmaceutical company really changed its strategy?
AGN: 208.47 (-2.67), VRX: 138.71 (-0.18)
Jim Cramer on the Stock Market: Activists Give Up on the Losers
at The Street - Wed Dec 10, 7:48AM CST
And that's too bad, because United Tech and McDonald's are begging for turnarounds.
AGN: 208.47 (-2.67), GE: 24.89 (-0.52), UTX: 112.15 (-1.89), MCD: 90.62 (-0.35), DOW: 43.35 (-2.66), WEN: 8.71 (+0.03), PEP: 94.74 (-1.55), BKW: 35.50 (-1.16)
Jim Cramer's 'Mad Money' Recap: Why Tuesday's Market Decline Made Sense
at The Street - Tue Dec 09, 7:32PM CST
The international markets pulled U.S. stocks lower but they were able to bounce back despite bad news from Verizon, Bank of America and Citi.
EA: 44.90 (-0.22), HON: 95.88 (-2.01), UTX: 112.15 (-1.89), C: 53.40 (-1.11), SNE: 20.33 (-0.41), BBY: 36.85 (+0.22), PEP: 94.74 (-1.55), AGN: 208.47 (-2.67), ATVI: 19.90 (-0.44), ETP: 60.56 (-1.13), SAVE: 68.12 (-0.88), TRGP: 92.56 (-0.45), WMB: 42.76 (-1.37), TEX: 26.48 (-0.43), AYR: 20.00 (-1.15), CAT: 90.50 (-2.19), MSFT: 46.95 (-0.22), UNP: 112.55 (-1.80), GME: 32.30 (-1.61), PDS: 5.39 (-0.07), BAC: 17.13 (-0.34), BKW: 35.50 (-1.16), MHR: 3.32 (-0.14), CONN: 17.44 (+0.35), MRK: 57.72 (-1.62), FLS: 54.87 (-2.45), MCD: 90.62 (-0.35), BRK.B: 146.46 (-3.67), VZ: 45.58 (-0.78), AMFW: 12.45 (-0.56), NRG: 26.66 (-0.26), WEN: 8.71 (+0.03)
Novartis Reports Encouraging Data on Biosimilar of Neupogen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 09, 2:15PM CST
Novartis (NVS) announced that its generic arm, Sandoz, reported encouraging data from a phase III study, PIONEER.
AGN: 208.47 (-2.67), INCY: 74.65 (-1.27), AMGN: 164.53 (-1.55), NVS: 93.52 (-0.82)
Wall Street Breakfast: China Stocks Tumble Most Since 2009
Wall Street Breakfast - Seeking Alpha - Tue Dec 09, 5:31AM CST
Economy European stocks fell for a second day as German imports and exports contracted in October, while Tesco ( OTCPK:TSCDF , OTCPK:TSCDY ) and energy companies plunged. German October imports slid 3.1% from a month earlier, while exports...
AMZN: 307.32 (-0.04), DRC: 80.82 (-0.03), VRX: 138.71 (-0.18), TLM: 4.29 (+0.60), C: 53.40 (-1.11), DB: 30.78 (-0.56), FIVE: 37.39 (+0.24), HSP: 60.33 (-1.75), ARO: 2.31 (+0.09), AGN: 208.47 (-2.67), PBR: 7.11 (-0.31), SPY: 200.89 (-3.30), QQQ: 102.67 (-1.13), CBST: 96.31 (+0.04), SMFG: 7.18 (-0.08), BHP: 46.18 (-0.92), MRK: 57.72 (-1.62), HMC: 29.34 (-0.72)
Bristol-Myers Posts Positive Opdivo Hodgkin Lymphoma Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 08, 4:10PM CST
Bristol-Myers Squibb Company (BMY) announced encouraging data from the ongoing phase Ib CheckMate - 039 study on Opdivo.
AGN: 208.47 (-2.67), ACT: 259.00 (-4.00), SGEN: 32.25 (-1.49), BMY: 58.75 (-0.93)
Agios (AGIO) Reports Encouraging Data on Leukemia Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 08, 3:35PM CST
Agios Pharmaceuticals, Inc. (AGIO) announced new data from the ongoing phase I dose escalation study on pipeline candidate AG-221.
AGN: 208.47 (-2.67), BIIB: 344.49 (+2.16), AGIO: 119.56 (+0.36), CELG: 114.49 (-2.25)
Novartis (NVS) Presents Additional Data on Leukemia Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 08, 2:30PM CST
Novartis (NVS) announced data on pipeline candidate, CTL019 from a long-term study of pediatric patients suffering from acute lymphoblastic leukemia (ALL).
AGN: 208.47 (-2.67), VRX: 138.71 (-0.18), ABBV: 65.27 (-1.76), NVS: 93.52 (-0.82)
Merck's New Oncology Product Positive in Early Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 08, 2:10PM CST
Merck (MRK) announced encouraging early results from the ongoing phase Ib study on Keytruda.
AGN: 208.47 (-2.67), SGEN: 32.25 (-1.49), MRK: 57.72 (-1.62), BMY: 58.75 (-0.93)
Is It Time to Buy This Growth Stock?
George Budwell, The Motley Fool - Motley Fool - Mon Dec 08, 8:43AM CST
Pharmaceutical stocks have absolutely soared amid the broader bull market. Shares of the specialist and generic drugmaker Actavis plc , for example, have more than tripled in value since 2012 alone: Actavis' rocket-like trajectory, though,...
AGN: 208.47 (-2.67), VRX: 138.71 (-0.18), ACT: 259.00 (-4.00), CBST: 96.31 (+0.04), PFE: 30.95 (-0.70), PDLI: 7.41 (-0.08)
Why 2014 Is the Biggest Year for Deals Since the Financial Crisis
at The Street - Mon Dec 08, 5:10AM CST
U.S. M&A jumped 38% in the first 10 months of the year from a year earlier, and is likely to mark the strongest year for deals since 2008 financial crisis.
ACT: 259.00 (-4.00), TERP: 27.50 (-1.34), MDT: 72.52 (-1.25), CHTR: 162.95 (-1.21), TWX: 82.12 (-1.19), AGN: 208.47 (-2.67), T: 32.16 (-0.55), FOX: 35.46 (-0.29), EBAY: 55.77 (-1.01), DTV: 83.47 (-0.43), JDSU: 13.81 (+0.06), GTIV: 19.05 (unch), WAG: 74.50 (+1.49), BHI: 54.99 (-0.78), KND: 18.61 (+0.54), ABT: 43.69 (-0.77), EXC: 35.92 (-0.35), COV: 100.49 (-1.36), HAL: 37.93 (-0.30), TSN: 40.80 (-0.93), HPQ: 38.01 (-0.46), SYMC: 25.26 (-0.58), ZTS: 41.77 (-1.11), POM: 26.66 (-0.30), SUNE: 18.55 (-0.47), GIS: 52.10 (-0.38), PETM: 77.67 (-0.77)
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2014
M2 - Mon Dec 08, 3:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/9mp6p4/wet_neovascular) has announced the addition of the "Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Wet (Neovascular / Exudative) Macular Degeneration - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Wet (Neovascular / Exudative) Macular Degeneration pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Alcon Nordic - Allergan - AlphaMab - Amakem - BIOCAD - Boehringer Ingelheim - Charlesson - Circadian Technologies - EyeCyte - EyeGate Pharmaceuticals - F. Hoffmann-La Roche - Genzyme - Icon Bioscience - Iconic Therapeutics - Intas Pharmaceuticals - Kala Pharmaceuticals - Lpath - Mesoblast - Neurotech Pharmaceuticals - Novartis - Ohr Pharmaceutical - Omeros Corporation - Ophthotech - Oxford BioMedica - PanOptica - Pfenex - Pfizer - Quark Pharmaceuticals - Regeneron Pharmaceuticals - Santen Pharmaceutical - Sanwa Kagaku Kenkyusho - Senju Pharmaceutical - TRACON Pharmaceuticals - Tacere Therapeutics - ThromboGenics - iCo Therapeutics - pSivida For more information visit http://www.researchandmarkets.com/research/9m...eovascular
AGN: 208.47 (-2.67), EYEG: (), OHRP: 8.55 (unch), REGN: 416.44 (-7.91), OMER: 22.81 (+0.12), NVS: 93.52 (-0.82)
